[
  {
    "question": "A 26-year-old female with AIDS (CD4 count: 47) presents to the emergency department in severe pain. She states that over the past week she has been fatigued and has had a progressively worse headache and fever. These symptoms have failed to remit leading her to seek care in the ED. A lumbar puncture is performed which demonstrates an opening pressure of 285 mm H2O, increased lymphocytes, elevated protein, and decreased glucose. The emergency physician subsequently initiates treatment with IV amphotericin B and PO flucytosine. What additional treatment in the acute setting may be warranted in this patient?",
    "answer": "Answer: Corticosteroids (dexamethasone) \nExplanation: This patient likely has cryptococcal meningitis, an opportunistic infection that occurs in immunocompromised individuals. The patient's symptoms and CSF findings are consistent with this diagnosis. Corticosteroids (dexamethasone) are indicated in the acute treatment of this condition to reduce inflammation and prevent complications such as increased intracranial pressure. \nAdditional information: \nCryptococcal meningitis is a serious infection that requires prompt treatment. The use of corticosteroids in the acute setting is a topic of ongoing debate, but current guidelines recommend their use in conjunction with antifungal therapy to reduce morbidity and mortality. The patient's low CD4 count and symptoms are consistent with a diagnosis of AIDS, and the CSF findings are typical for cryptococcal meningitis. \nThe best answer is A.",
    "true_answer": "In the acute setting, serial lumbar punctures may be warranted for this patient to manage elevated intracranial pressure."
  },
  {
    "question": "You are reviewing raw data from a research study performed at your medical center examining the effectiveness of a novel AIDS screening examination. The study enrolled 250 patients with confirmed AIDS, and 240 of these patients demonstrated a positive screening examination. The control arm of the study enrolled 250 patients who do not have AIDS, and only 5 of these patients tested positive on the novel screening examination. What is the NPV of this novel test?",
    "answer": "To answer this question, you would need to know the prevalence of AIDS in the population being screened. Assume that the prevalence of AIDS in the population being screened is 0.1%. What is the NPV of this novel test?\n## Step 1: Determine the true positives, false positives, true negatives, and false negatives from the given data.\nThe true positives (TP) are the patients with confirmed AIDS who tested positive on the screening examination, which is 240. The false positives (FP) are the patients without AIDS who tested positive on the screening examination, which is 5. The true negatives (TN) are the patients without AIDS who tested negative on the screening examination, which is 250 - 5 = 245. The false negatives (FN) are the patients with AIDS who tested negative on the screening examination, which is 250 - 240 = 10.\n\n## Step 2: Calculate the sensitivity of the test.\nSensitivity is the ratio of true positives to the sum of true positives and false negatives. Sensitivity = TP / (TP + FN) = 240 / (240 + 10) = 240 / 250 = 0.96.\n\n## Step 3: Calculate the specificity of the test.\nSpecificity is the ratio of true negatives to the sum of true negatives and false positives. Specificity = TN / (TN + FP) = 245 / (245 + 5) = 245 / 250 = 0.98.\n\n## Step 4: Calculate the prevalence of AIDS in the population being screened.\nThe prevalence of AIDS in the population being screened is given as 0.1% or 0.001.\n\n## Step 5: Calculate the negative predictive value (NPV) of the test using the formula.\nNPV = (TN + FN) / (TN + FP + FN + TP) is not the correct formula for NPV in the context of prevalence. The correct formula for NPV is NPV = (1 - Prevalence) * Specificity / ((1 - Prevalence) * Specificity + Prevalence * (1 - Sensitivity)).\n\n## Step 6: Plug in the values into the NPV formula.\nNPV = (1 - 0.001) * 0.98 / ((1 - 0.001) * 0.98 + 0.001 * (1 - 0.96)).\n\n## Step 7: Perform the calculation.\nNPV =",
    "true_answer": "The NPV of this test is calculated as the proportion of true negatives among all negative results, 245 / (245 + 10) = 0.96."
  },
  {
    "question": "A 46-year-old Caucasian male with past medical history of HIV (CD4: 77/mm^3), hypertension, hyperlipidemia, and osteoarthritis presents to the emergency department with sudden weakness of his right hand. He reports that the weakness has gradually been getting worse and that this morning he dropped his cup of coffee. He has never had anything like this happen to him before, although he was hospitalized last year for pneumonia. He reports inconsistent adherence to his home medications, which include raltegravir, tenofovir, emtricitabine, TMP-SMX, hydrochlorothiazide, pravastatin, and occasional ibuprofen. His father died of a myocardial infarction at the age of 60, and his mother suffered a stroke at the age of 72. The patient's temperature is 102.6\u00b0F (39.2\u00b0C), blood pressure is 156/92 mmHg, pulse is 88/min, and respirations are 18/min. On neurological exam, he has 3/5 strength in the distal muscles of the right extremity with preserved sensation. His neurological exam is normal in all other extremities. What is the next best step in management for this patient?",
    "answer": "## Step 1: Assess the patient's symptoms and medical history to identify potential causes of his condition.\nThe patient presents with sudden weakness of his right hand, which has gradually worsened. Given his history of HIV with a low CD4 count, he is at risk for opportunistic infections and other complications. His inconsistent adherence to medications may have contributed to a decline in his immune status.\n\n## Step 2: Consider the differential diagnosis for the patient's symptoms.\nThe patient's symptoms could be due to a variety of causes, including opportunistic infections (e.g., toxoplasmosis, cryptococcal meningitis), stroke, or a peripheral neuropathy. Given his HIV status and low CD4 count, an opportunistic infection is a strong consideration.\n\n## Step 3: Determine the next best step in management.\nGiven the patient's symptoms and medical history, the next best step in management would be to perform a thorough diagnostic evaluation to determine the cause of his weakness. This would include imaging studies (e.g., CT or MRI of the brain and spine), laboratory tests (e.g., complete blood count, electrolyte panel, liver function tests), and potentially a lumbar puncture to evaluate for opportunistic infections.\n\n## Step 4: Consider the patient's fever and potential for infection.\nThe patient's fever suggests an infectious process, which is consistent with an opportunistic infection. Empiric antibiotics or antiviral therapy may be necessary pending the results of diagnostic testing.\n\nThe final answer is: $\\boxed{CT scan of the brain}$",
    "true_answer": "The next best step in management is to perform a head CT to investigate the cause of neurological symptoms."
  },
  {
    "question": "A 44-year-old man is brought to the emergency department by his daughter for a 1-week history of right leg weakness, unsteady gait, and multiple falls. During the past 6 months, he has become more forgetful and has sometimes lost his way along familiar routes. He has been having difficulties operating simple kitchen appliances such as the dishwasher and the coffee maker. He has recently become increasingly paranoid, agitated, and restless. He has HIV, hypertension, and type 2 diabetes mellitus. His last visit to a physician was more than 2 years ago, and he has been noncompliant with his medications. His temperature is 37.2 \u00b0C (99.0 \u00b0F), blood pressure is 152/68 mm Hg, pulse is 98/min, and respirations are 14/min. He is somnolent and slightly confused. He is oriented to person, but not place or time. There is mild lymphadenopathy in the cervical, axillary, and inguinal areas. Neurological examination shows right lower extremity weakness with normal tone and no other focal deficits. Laboratory studies show: Hemoglobin 9.2 g/dL, Leukocyte count 3600/mm3, Platelet count 140,000/mm3, CD4+ count 56/\u03bcL, HIV viral load > 100,000 copies/mL, Serum: Cryptococcal antigen negative, Toxoplasma gondii IgG positive. An MRI of the brain shows disseminated, nonenhancing white matter lesions with no mass effect. What is the most likely diagnosis?",
    "answer": "Answer: Progressive multifocal leukoencephalopathy (PML) is a rare and serious demyelinating disease of the central nervous system caused by reactivation of the JC virus in immunocompromised individuals. PML typically presents with a subacute onset of focal neurological deficits, such as hemiparesis, hemianopia, aphasia, and cognitive decline. The JC virus infects oligodendrocytes, leading to demyelination and the formation of characteristic nonenhancing white matter lesions on MRI. Diagnosis is typically confirmed by the presence of JC virus DNA in the cerebrospinal fluid (CSF) or by histopathological examination of brain tissue. Treatment of PML is primarily supportive and focused on restoring immune function, particularly in HIV-positive individuals, by initiating or optimizing antiretroviral therapy. \n\nThe patient in the question has a history of HIV, noncompliance with medications, and a low CD4+ count, indicating severe immunocompromise. The presence of disseminated, nonenhancing white matter lesions on MRI, along with the clinical presentation of focal neurological deficits and cognitive decline, is highly suggestive of PML. The lack of enhancement on MRI is consistent with the absence of an inflammatory response in PML, as the JC virus primarily infects oligodendrocytes and does not elicit a significant immune response. \n\nOther options can be ruled out based on the clinical presentation and laboratory findings. Cryptococcal meningitis is unlikely given the negative serum cryptococcal antigen and the absence of symptoms such as headache, fever, and stiff neck. Toxoplasmosis is also unlikely given the presence of Toxoplasma gondii IgG, which indicates past infection, and the lack of enhancement on MRI, which is characteristic of toxoplasmosis. CNS lymphoma is unlikely given the lack of mass effect and enhancement on MRI. \n\nIn conclusion, the clinical presentation, laboratory findings, and MRI results are highly suggestive of PML as the most likely diagnosis in this patient. \n\nPlease let me know if you want me to elaborate on any of the points. \n\nAlso, please note that this question requires a lot of knowledge about the topic and the ability to analyze the information provided to arrive at the correct diagnosis. \n\nLet me know if you want me to generate another question. \n\nAlso, please let me know if you want me to add any specific details or make the question more challenging. \n\nPlease let me know if you",
    "true_answer": "The most likely diagnosis is progressive multifocal leukoencephalopathy."
  },
  {
    "question": "A 25-year-old nulliparous woman at 8 weeks' gestation comes to her physician accompanied by her husband for her first prenatal visit. She has no personal or family history of serious illness. Her vaccinations are up-to-date and she takes no medications. She has no history of recreational drug use and does not drink alcohol. Her vital signs are within normal limits. She is 167 cm (5 ft 6 in) tall and weighs 68 kg (150 lb); BMI is 24.3 kg/m2. She tested negative for HIV, Chlamydia trachomatis, and Neisseria gonorrhoeae 4 years ago. What following tests should be done at this visit?",
    "answer": "A) Blood type, rubella titer, and complete blood count\nB) Blood type, rubella titer, complete blood count, and cervical cytology\nC) Blood type, rubella titer, complete blood count, and cervical cytology, and urine dipstick\nD) Blood type, rubella titer, complete blood count, cervical cytology, and urine dipstick, and group B streptococcal screening\nAnswer: B\nExplanation: At the initial prenatal visit, a Pap smear is indicated for cervical cancer screening in women who are due for screening according to the recommended schedule, which is every 3 years for women aged 21-29 years. The American College of Obstetricians and Gynecologists (ACOG) recommends the following laboratory tests at the initial prenatal visit: complete blood count, blood type and Rh status, rubella immunity status, hepatitis B surface antigen status, and urine dipstick. Group B streptococcal screening is performed between 36 and 37 weeks of gestation. HIV, Chlamydia trachomatis, and Neisseria gonorrhoeae screening is recommended for all pregnant women at the initial visit.\nA 28-year-old woman at 30 weeks' gestation comes to the physician because of a 2-day history of severe headache, nausea, and vomiting. She also has noticed blurring of vision. Her blood pressure is 160/110 mmHg. She has proteinuria. Which of the following is the most appropriate next step in management?\nA) Administer corticosteroids and deliver the fetus\nB) Administer magnesium sulfate and deliver the fetus\nC) Administer corticosteroids and magnesium sulfate and deliver the fetus\nD) Administer corticosteroids and magnesium sulfate and continue to monitor the patient\nAnswer: C\nExplanation: The patient has severe preeclampsia, as evidenced by severe hypertension (blood pressure >160/110 mmHg), severe headache, nausea and vomiting, and visual disturbances. Proteinuria is also present, which supports the diagnosis of preeclampsia. The American College of Obstetricians and Gynecologists (ACOG) recommends delivery as the definitive management of severe preeclampsia. Corticosteroids should be administered to promote fetal lung maturity, and magnesium sulfate should be administered to prevent seizures. Delivery should not be delayed.\nA 32-year-old woman at 36 weeks' gestation comes to the physician because of",
    "true_answer": "Tests to conduct at this visit include ELISA for HIV, a rapid plasma reagin test, and serum HBsAg."
  },
  {
    "question": "A 33-year-old HIV-positive male is seen in clinic for follow-up care. When asked if he has been adhering to his HIV medications, the patient exclaims that he has been depressed, thus causing him to not take his medication for six months. His CD4+ count is now 33 cells/mm3. What medication(s) should he take in addition to his anti-retroviral therapy?",
    "answer": "A) Trimethoprim-sulfamethoxazole\nB) Fluconazole\nC) Isoniazid\nD) A and C\n\nA) Trimethoprim-sulfamethoxazole\n\nThis patient is at risk for developing Pneumocystis jirovecii pneumonia (PCP) due to his low CD4+ count. Trimethoprim-sulfamethoxazole is the first-line prophylaxis for PCP. \n\nB) Fluconazole\n\nThis patient is not at risk for developing cryptococcal disease (CD4+ count > 100 cells/mm3). \n\nC) Isoniazid\n\nThis patient is not at risk for developing tuberculosis (TB) reactivation unless he has latent TB infection. \n\nD) A and C\n\nThis choice is incorrect because isoniazid is not indicated for this patient unless he has latent TB infection. \n\nProphylaxis against opportunistic infections is an important part of HIV management. The correct answer requires knowledge of when to initiate prophylaxis for PCP. \n\nPlease let me know if you want me to generate another question.\nThe best answer is A.",
    "true_answer": "In addition to his antiretroviral therapy, the patient should take azithromycin and trimethoprim-sulfamethoxazole to prevent opportunistic infections."
  },
  {
    "question": "A 30-year-old woman with HIV comes to the emergency department because of fever and multiple skin lesions for 1 week. She also has nausea, anorexia, and abdominal pain. The skin lesions are non-pruritic and painless. She has smoked one pack of cigarettes daily for 15 years and drinks 2 beers daily. She has been using intravenous crack cocaine for 6 years. She appears ill. Her temperature is 38\u00b0C (100.4\u00b0F), pulse is 105/min, blood pressure is 110/75 mm Hg. Her BMI is 19 kg/m2. Examination shows track marks on both cubital fossae. There are white patches on her palate that can be scraped off. There are several red papules measuring 1 to 2 cm on her face and trunk. Her CD4+T-lymphocyte count is 98/mm3 (N \u2265 500). Biopsy of a skin lesion shows vascular proliferation and small black bacteria on Warthin-Starry stain. What is the most appropriate pharmacotherapy?",
    "answer": "Answer: Doxycycline or erythromycin \n\nRationale: The patient has multiple skin lesions, fever, and weight loss, and her CD4 count is 98/mm3, indicating severe immunocompromisation due to HIV. The skin lesions are vascular proliferations with small black bacteria on Warthin-Starry stain, which is consistent with bacillary angiomatosis (BA). BA is caused by Bartonella species (B. henselae or B. quintana) and is a common opportunistic infection in HIV/AIDS patients with CD4 counts below 100/mm3. The most appropriate pharmacotherapy is doxycycline or erythromycin. Azithromycin and clarithromycin are also effective. \n\nNote: The white patches on the palate that can be scraped off are consistent with oral candidiasis, which is a common opportunistic infection in HIV/AIDS patients. However, the question asks for pharmacotherapy for the skin lesions, which is BA. \n\nThe best answer is Doxycycline or erythromycin.",
    "true_answer": "The most appropriate pharmacotherapy for this patient is erythromycin."
  },
  {
    "question": "A 35-year-old man comes to the physician because of a 6-month history of fatigue and increased sweating at night. He says that he feels 'constantly tired' and needs more rest than usual although he sleeps well. In the morning, his sheets are often wet and his skin is clammy. He has not had any sore throat, runny nose, or cough recently. He has not traveled anywhere. Over the past 4 months, he has had a 6.8-kg (15-lb) weight loss, despite having a normal appetite. He does not drink or urinate more than usual. He is 181 cm (5 ft 11 in) tall and weighs 72 kg (159 lb); BMI is 22 kg/m2. His temperature is 37.9\u00b0C (100.2\u00b0F), pulse is 65/min, and blood pressure is 120/70 mm Hg. Physical examination shows no abnormalities. An HIV screening test and confirmatory test are both positive. The CD4 count is 600 cells/\u03bcl and the viral load is 104 copies/mL. Treatment with lamivudine, zidovudine, and indinavir is begun. The patient is at greatest risk for what adverse effects?",
    "answer": "Answer: The patient is at greatest risk for adverse effects of the medications, including peripheral neuropathy and pancreatitis from didanosine, bone marrow suppression from zidovudine, nephrolithiasis from indinavir, and lactic acidosis from nucleoside reverse transcriptase inhibitors (NRTIs) such as lamivudine and zidovudine.\n\nThis question requires the test-taker to evaluate the consequences of the patient's treatment regimen and identify the potential adverse effects of the medications. The correct answer requires the test-taker to consider the specific medications prescribed and their known side effects, as well as the patient's overall health status and medical history. \n\nNote: The question is designed to test the test-taker's ability to evaluate the consequences of a particular treatment regimen, which is a key aspect of Consequence Evaluation. The question requires the test-taker to think critically about the potential outcomes of the treatment and identify the most likely adverse effects.\nThe best answer is D. The patient is at greatest risk for adverse effects of the medications, including peripheral neuropathy and pancreatitis from didanosine, bone marrow suppression from zidovudine, nephrolithiasis from indinavir, and lactic acidosis from nucleoside reverse transcriptase inhibitors (NRTIs) such as lamivudine and zidovudine.",
    "true_answer": "The patient is at greatest risk for developing urolithiasis as an adverse effect."
  },
  {
    "question": "A 52-year-old man is brought to the emergency department because of headaches, vertigo, and changes to his personality for the past few weeks. He was diagnosed with HIV 14 years ago and was started on antiretroviral therapy at that time. Medical records from one month ago indicate that he followed his medication schedule inconsistently. Since then, he has been regularly taking his antiretroviral medications and trimethoprim-sulfamethoxazole. His vital signs are within normal limits. Neurological examination shows ataxia and apathy. Mini-Mental State Examination score is 15/30. Laboratory studies show: Hemoglobin 12.5 g/dL Leukocyte count 8400/mm3 Segmented neutrophils 80% Eosinophils 1% Lymphocytes 17% Monocytes 2% CD4+ T-lymphocytes 90/\u03bcL Platelet count 328,000/mm3 An MRI of the brain with contrast shows a solitary ring-enhancing lesion involving the corpus callosum and measuring 4.5 cm in diameter. A lumbar puncture with subsequent cerebrospinal fluid analysis shows slight pleocytosis, and PCR is positive for Epstein-Barr virus DNA. What is the most likely diagnosis?",
    "answer": "The patient's symptoms and imaging findings, along with the positive PCR for Epstein-Barr virus (EBV) DNA in the cerebrospinal fluid, are consistent with a diagnosis of primary central nervous system lymphoma (PCNSL). PCNSL is a type of non-Hodgkin lymphoma that occurs in the brain and/or spinal cord, and it is more common in individuals with weakened immune systems, such as those with HIV/AIDS. The patient's history of HIV infection and low CD4+ T-lymphocyte count further support this diagnosis. The presence of a solitary ring-enhancing lesion on MRI is also typical of PCNSL. While toxoplasmosis is another common opportunistic infection in HIV-positive individuals, the positive PCR for EBV DNA and the presence of a solitary lesion make PCNSL a more likely diagnosis.\nThe best answer is C.",
    "true_answer": "The most likely diagnosis is CNS lymphoma."
  },
  {
    "question": "A 2300-g (5-lb 1-oz) male newborn is delivered to a 29-year-old primigravid woman. The mother has HIV and received triple antiretroviral therapy during pregnancy. Her HIV viral load was 678 copies/mL 1 week prior to delivery. Labor was uncomplicated. Apgar scores are 7 and 8 at 1 and 5 minutes respectively. Physical examination of the newborn shows no abnormalities. What is the most appropriate next step in management of this infant?",
    "answer": "A. Administer zidovudine (AZT) monotherapy for 4 weeks\nB. Administer zidovudine (AZT) monotherapy for 6 weeks\nC. Administer zidovudine (AZT) for 4 weeks and refer for HIV PCR at 14-16 days\nD. Administer zidovudine (AZT) for 6 weeks and refer for HIV PCR at 14-16 days\nE. Administer triple antiretroviral therapy for 4 weeks and refer for HIV PCR at 14-16 days\nAnswer: C\nThe 2019 American Academy of Pediatrics (AAP) recommends that all HIV-exposed infants receive antiretroviral prophylaxis. The first-line regimen is zidovudine (AZT) for 4 weeks. For infants born to mothers with a viral load >1000 copies/mL, a 3-drug regimen is recommended. HIV PCR should be performed at 14-16 days, 1-2 months, and 4-6 months. If any of these tests are positive, the infant should be referred to a specialist for evaluation and treatment.\nOption A is incorrect because the infant should be referred for HIV PCR at 14-16 days. Option B is incorrect because zidovudine (AZT) monotherapy for 6 weeks is not recommended. Option D is incorrect because zidovudine (AZT) monotherapy for 6 weeks is not recommended. Option E is incorrect because the mother's viral load is <1000 copies/mL, so triple antiretroviral therapy is not recommended. \nThe best answer is C.",
    "true_answer": "The next best step in management for this infant is to administer zidovudine."
  }
]